COVID-19 Delta Surges
The final days of the pandemic may feel like a prolonged good-bye, but for regions facing local surges in viral ...
Rise of Physician Advocates
Patient advocacy permeates all aspects of healthcare, including regulatory processes. But lacking in the newfound emphasis on patient input is ...
Post-Pandemic Opioid Litigation
As Mark Twain said, history does not repeat itself, but it often rhymes. As the current wave of opioid litigation ...
Healthcare Hybridization
Healthcare never advances along a simple course, it is always a convoluted mix of what is predicted and unanticipated - ...
Healthcare Consumerism
Population health has never been more in demand, with hospitals unveiling many new care models. But rather than the care ...
A Medical Decision, Made Legally
With the CDC's abrupt decision to lift all mask mandates, businesses were left to decide whether to maintain the mandates. ...
What is Data, Really?
The FDA recently approved a drug touted to treat Alzheimer's Disease. A decision decried by policy experts as data supporting ...
Trust and Distrust
Vaccine hesitancy is pervasive among patients, even among those who opt to receive it. Yet physicians continue to denounce the ...
Of Systems and Attributions
Of all the issues plaguing healthcare, none is more pressing than our inability to see healthcare as a complex system. ...
Healthcare is Irrational
One Medical acquired Iora Health, a surprising integration of two vastly different companies that does not make sense at first ...
Medical Devices & Patient Advocacy
If perception is reality, then the changing perception of post-pandemic healthcare has ushered in a new reality for the medical ...
Disparity Masquerading As Equity
There is much talk about healthcare equity, and the importance of access in healthcare. But access means different things to ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more